Stock ATRA ATARA BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.6115 USD -2.00% Intraday chart for Atara Biotherapeutics, Inc. -13.87% +19.25%
May. 20 Sector Update: Health Care Stocks Ease Monday Afternoon MT
May. 20 Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Ease Monday Afternoon
Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy
Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis
Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology
Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024
Atara Biotherapeutics, Inc. Announces Closing of Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories
Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Sector Update: Health Care Stocks Falling Late Afternoon
Atara Biotherapeutics
Top Midday Decliners
Wall Street Set to Open Higher Thursday as Jobless Claims Fall, Ahead of Powell Speech
Investors Await Jobless Claims Report, Powell Speech as US Futures Remain Flat in Thursday Trading
Top Premarket Decliners
Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
Atara Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATRA Stock
  4. News Atara Biotherapeutics, Inc.
  5. Other languages